Gujarat Themis Biosyn Limited — PPTs, 20-05-2025: Investor Presentation

1. Financial Highlights:

Gujarat Themis Biosyn reported revenue of Rs. 150.8 Cr for FY25, down 11.2% YoY, attributed to inventory volatility. EBITDA stood at Rs. 68.8 Cr with a margin of 45.7%, slightly down by 71 bps. PAT was Rs. 48.8 Cr, down 17.5% YoY, with a margin of 32.3%, and EPS declined to Rs. 4.48. Quarterly performance showed softness from inventory fluctuations affecting topline and margins. The balance sheet remains solid with total equity of Rs. 248.4 Cr, low borrowings, and capital employed increased to Rs. 225 Cr due to ongoing capex in property, plant & equipment and CWIP.

2. Strategic Initiatives & Growth Drivers:

The company is scaling up fermentation capacity and has initiated a new API unit as part of forward integration targeting the US and European markets. R&D investment rose to 12% of sales, focusing on new molecule development through upgraded facilities. Infrastructure enhancements and environmental clearances are in progress to support capacity growth and product diversification.

3. Business Developments:

Commercial production commenced at the new API facility, with batch validation ongoing. GTBL is advancing development of intermediate molecules and pursuing organic and inorganic growth in specialty chemicals. Collaborations and partnerships are reinforcing manufacturing capabilities and broadening the product portfolio.

4. Market Position & Competitive Advantage:

GTBL holds a niche position as one of India’s few fermentation-based intermediate producers, with expertise in rifamycin intermediates and APIs. Its advanced manufacturing setup, low debt, and strong cash flows enable competitive advantage. Forward integration and robust R&D back scale and differentiation domestically and internationally.

5. Investor Implications:

Growth potential looks positive powered by capacity expansions, forward integration, and R&D focus, despite short-term margin pressures from investments and inventory shifts. Execution risk centers on ramping new facilities and scaling exports. Strong financial health and API production readiness support confidence in medium-term value creation.